The Association between Long Noncoding RNA over Expression and Poor Prognosis of Liver Cancer: A Meta-Analysis

Leiqing Wang,1 Junzhi Sheng,1 Haojie Zhang,2 Baoyuan Xie,3 Linbiao Xiang,3 Dong Liu,4 Xinyuan Zhang,5 Peihao Zhang,3 and Jinjin Liu1,6

1The First School of Clinical Medicine of Lanzhou University, Lanzhou 730000, Gansu, China
2Department of Clinical Medicine, Medical College, Wuhan University of Science and Technology, Wuhan 430065, Hubei, China
3The Second School of Clinical Medicine of Lanzhou University, Lanzhou 730000, Gansu, China
4The School of Clinical Medicine of Shi Hezi University, Shi Hezi 832000, Xinjiang, China
5The School of Clinical Medicine of Weifang Medical University, Weifang 261000, Shandong, China
6Department of Endocrinology, The First Hospital of Lanzhou University, No. 1 West Donggang Road, Lanzhou, Gansu 730000, China

Correspondence should be addressed to Jinjin Liu; liujj19@lzu.edu.cn

Received 10 October 2021; Revised 19 October 2021; Accepted 26 October 2021; Published 24 November 2021

Abstract

Background. Long noncoding RNA (lncRNA) is considered to be a mediator of carcinogenesis, which may be associated with liver cancer survival. However, the relationship remains inconclusive. Meta-analysis was conducted to analytically review the association between the lncRNA expression level and clinicopathological characteristics and prognostic value of hepatic carcinoma.

Materials and Methods. Four databases including Embase, PubMed, Web of Science, and the Cochrane Library were searched to collect studies about the relation between lncRNA overexpression and prognosis of liver cancer, dating from the earliest records of these databases to March 2021. Two researchers independently screened the data and literature to perform a stringent evaluation of the quality of material involved in the study. Meta-analysis was performed by Stata 16.0 software on 42 case-control studies with 6293 samples. Results. The outcomes of meta-analysis are presented as follows: lncRNA overexpression patients had later TNM stage (OR = 0.36, 95% CI (0.31, 0.41), P < 0.001), lower histological grade (OR = 0.56, 95% CI (0.49, 0.65), P < 0.001), more vascular invasion (OR = 2.02, 95% CI (1.74, 2.35), P < 0.001), bigger tumor size (OR = 2.28, 95% CI (2.00, 2.60), P < 0.001), more severe liver cirrhosis (OR = 1.39, 95% CI (1.16, 1.66), P < 0.001), more likely to metastasize (OR = 1.80, 95% CI (1.49, 2.18), P < 0.001), and more tumor numbers (OR = 0.72, 95% CI (0.62, 0.84), P < 0.05). lncRNA over expression patients had shorter OS (HR = 2.32, 95% CI (2.08, 2.59), P < 0.01), RFS (HR = 2.19, 95% CI (1.72, 2.78), P < 0.01), and DFS (HR = 2.01, 95% CI (1.57, 2.57), P < 0.01).

Conclusions. Overexpression of lncRNA is a poor prognostic feature for patients with hepatic carcinoma. The scope of our study was limited because of a lack of relevant research and the poor representativeness and varying quality of the studies involved in the current meta-analysis. Our conclusion still requires higher studies for further validation. This trial is clinically registered with CRD4201920620.

1. Introduction

Hepatic carcinoma is one of the most commonly occurring malignant cancers, with morbidity and mortality ranked sixth and second, respectively, causing serious threats to human health [1, 2]. According to statistics in 2012, there are about 780,000 novel patients reported and 740,000 deaths across the globe. The incidence of China accounts for 50%, and it shows an upward trend [3]. So far, it is believed that genetic and environmental factors, both cause tumorigenesis, but the specific pathogenesis of liver cancer has not been completely clarified. Currently, surgical treatment is still the most effective and radically curable method, but a considerable number of patients with liver cancer cannot be suffered from surgery or have lost the best time for surgery. Therefore, it is urgently necessary to find new effective
markers that are specifically expressed in hepatic malignant to improve the diagnosis and the accuracy of judgment on prognosis. Over the last few years, the function of long noncoding RNA (lncRNA) in many pathological and physiological pathways has been gradually explored, and it is also aberrantly expressed in some malignant tumors, regulating the spread, variation, and metastasis of cancerous cells [4].

lncRNA is a kind of endogenic RNA 200 or more nucleotides long, which is extensively present in Homo sapiens. It has no protein-coding function and lacks a specific open reading frame (ORF) [5], which was considered to be a nonsignificant byproduct of transcription in the early stage [6–8]. Over the years, due to the advancement of high-resolution chips and high-throughput sequencing technologies, the research on transcriptome regulation has been increasingly deepened, and it is found that lncRNA not only plays a significant role in transcriptional interference but also in the process of some histological development, tumorigenesis, and tumor metastasis [9–11]. Researchers have found that aberrant expression of lncRNA affects the prognosis of liver cancer, associated with metastasis, TNM stage, and other clinicopathological characteristics of liver cancer [12]. Therefore, lncRNA could be a novel marker for the diagnosis, prognosis of liver cancer, and a possible therapeutic target for the cure of liver cancer. This study is the first to systematically evaluate the association of lncRNA, the expression quantity, and the clinical attributes and prognostic value in liver cancer patients, providing a basis for clinical practice.

2. Materials and Methods

2.1. Literature Search Strategy. We searched computers for EMBASE, PubMed, Web of Science databases, and the Cochrane Library to collect studies related to the correlation between high expression of lncRNA and prognosis of hepatic carcinoma. Only articles in English were selected. The following keywords were used: IncRNA, long ncRNA, lincRNAs, long noncoding RNA, long noncoding RNA, long untranslated RNA, liver neoplasm, hepatic neoplasm, hepatocellular cancer, liver cancer, cancer of the liver, etc. At the same time, manually search for references as a supplement.

2.2. Inclusion and Exclusion Standard. The standard for eligible articles is mentioned as (1) the case-control studies related to the correlation between high levels of lncRNA and prognosis of patients with hepatic carcinoma were published at home and abroad. (2) The affected individuals were diagnosed with hepatic carcinoma by cytological and histopathological examination. (3) The expression of lncRNA was quantified by reverse transcription-polymerase chain reaction (RT-PCR). (4) The cutoff value of lncRNA expression level was described. (5) Every study performed the association between expression of lncRNA and OS, and the hazard ratio (HR) value and its corresponding 95% confidence interval (95% CI) for OS was either obtained directly from actual study or indirectly it will be calculated by Engage Digitizer 4.1 software from survival curve. (6) No restrictions of age, race, gender, and region.

The study exclusion standard is as follows: (1) repetitive published literature; (2) non-Chinese and English literature; (3) literature is unable to obtain full-text; (4) literature that does not report liver cancer prognosis outcomes or that cannot extract ending data from the text.

2.3. Data Extraction. Two researchers independently screen literature and extract data. Third researcher will handle if any disagreement occurs. Data was gathered and extracted based on the following criteria: (1) the basic information includes the topic of the study, author, and publication year; (2) baseline features of the included article, which included sample size, region, lncRNA type, lncRNA expression level, whether preoperative treatment, a cutoff value, lncRNA test method and TNM staging of liver cancer, etc. (3) Outcome indicators: OS, RFS, DFS, TNM stage, histological grade, vascular invasion, tumor numbers, tumor size, location, etc. The hazard ratio (HR) value and its corresponding 95% confidence interval (95% CI) for the OS, RFS, and DFS were either directly acquired from the original text or will be indirectly estimated by Engage Digitizer 4.1 software from the survival curve [13]; (4) risk of bias assessed the key factors.

2.4. Quality Assessment of Included Studies. All the included studies were nonrandomized and retrospective studies. The quality was assessed using the Newcastle–Ottawa Scale (NOS). Each included study was assessed by two researchers for the quality from three mentioned items: “selection,” “comparability,” and “exposure.” There are evaluation items under each item, and each item is indicated by * when appropriate. The highest score of comparability is 2*. Any discrepancies were resolved by consensus.

2.5. Statistical Analysis. We use Stata 16.0 software to perform statistical analysis. \( P < 0.01 \) was considered statistically significant. The odds ratio (OR) and hazard ratio (HR) were used to analyze the effect statistics, and each effect provided a 95% CI. Heterogeneity between the comprised studies was analyzed using the \( I^2 \) test. \( I^2 < 50\% \) suggests no statistical heterogeneity between the outcomes of each research, using the fixed-effects model to perform the meta-analysis. Otherwise, the random-effect model would be used finally. After excluding the significant effects of clinical heterogeneity, use the random-effects model to perform the meta-analysis. Significant clinical heterogeneity is processed using methods such as subgroup analysis or sensitivity analysis [14].

3. Results

3.1. Literature Screening Process and Results. Overall, 4140 articles were retrieved in the early inspection. Later on, forty-two studies were finally included on layer-by-layer
screening. Figure 1 shows the literature screening process and outcomes.

3.2. Basic Characteristics and Quality Assessment Results of the Included Studies. General characteristics of liver cancer patients include age, gender, sample size, region, lncRNA type, lncRNA expression level, whether preoperative treatment, a cutoff value, etc. These all are shown in Table 1. Newcastle–Ottawa Scale (NOS) marked included studies to be of high quality. All the studies have a score greater than 5 stars and meet the criteria for inclusion in the meta-analysis. The results are listed in Table 2.

3.3. Meta-Analysis Results

3.3.1. Clinical Features. A total of 42 studies were included, including 6293 samples. Meta-analysis showed that patients with high expression of lncRNA had later TNM stage (OR = 0.36, 95% CI (0.31, 0.41), P < 0.001), lower histological grade (OR = 0.56, 95% CI (0.49, 0.65), P < 0.001), more vascular invasion (OR = 2.02, 95% CI (1.74, 2.35), P < 0.001), bigger tumor size (OR = 2.28, 95% CI (2.00, 2.60), P < 0.001), more severe liver cirrhosis (OR = 1.39, 95% CI (0.16, 1.66), P < 0.001), more likely to metastasize (OR = 1.80, 95% CI (1.49, 2.18), P < 0.001), more expression of AFP (OR = 1.46, 95% CI (1.22, 1.75), P < 0.001 and OR = 1.79, 95% CI (1.40, 2.29), P < 0.001), and more tumor numbers (OR = 0.72, 95% CI (0.62, 0.84), P < 0.05). The differences of other clinical features, such as age, gender, and HBV infection were not statistically significant. The results are shown in Table 3.

3.3.2. OS. A total of 29 studies were included. The meta-analysis of the fixed effects model (I² = 0.0%, P = 0.829) showed that compared with patients with low expression of lncRNA, patients of high expression of lncRNA have shorter OS. The difference was statistically significant (HR = 2.32, 95% CI% (2.08, 2.59), P < 0.01) (Figure 2).

3.3.3. RFS. A total of 4 studies [21, 24, 30, 54] were included. The meta-analysis of the fixed effects model (I² = 0.0%, P = 0.576) showed that compared with patients with low expression of lncRNA, patients with high expression of lncRNA have shorter RFS. The difference was statistically significant (HR = 2.19, 95% CI% (1.72, 2.78), P < 0.01) (Figure 3).

3.3.4. DFS. A total of 7 studies [16, 20, 29, 31, 33, 41, 52] were included. The meta-analysis of the fixed effects model (I² = 38.1%, P = 0.138) showed that compared with patients with low expression of lncRNA, patients with high expression of lncRNA have shorter DFS. The difference was...
Table 1: Basic characteristics of included studies.

| Study ID | Region | Sample Size | LncRNA | Cutoff Value | TNM Stage | Data extraction method | Follow-up (months) | Outcome | Postoperative treatment |
|----------|--------|-------------|--------|--------------|-----------|------------------------|------------------|---------|------------------------|
| Guo [15] | China  | 95          | NEAT1  | Median value | I–IV      | Survival curve          | No               | OS      | NO                     |
| Hua [10] | China  | 92          | ANRIL  | Median value | I–IV      | Reported in text        | 60               | OS      | NO                     |
| Li [16]  | China  | 179         | GHET1  | Median value | I–IV      | Reported in text        | No               | OS      | NO                     |
| Wang [17] | China  | 112         | HOTAIR | Median value | I–IV      | Survival curve          | No               | OS      | NO                     |
| Zhou [18] | China  | 109         | BANCR  | Median value | I–III     | Survival curve          | SDD              | OS      | NR                     |
| Ding [19] | China  | 137         | TUG1   | Median value | I–IV      | Reported in text        | 27.58            | OS      | NR                     |
| Ding [20] | China  | 214         | PVT1   | ROC analysis | I–IV      | Reported in text        | 27.58            | OS      | NR                     |
| Yang [21] | China  | 60          | HOXA-AS2 | Median value | I–IV     | Survival curve          | No               | OS      | NR                     |
| Yan [22]  | China  | 117         | PCAT-1 | Median ratio | —         | Reported in text        | 60               | OS      | NO                     |
| Zhang [23] | China  | 144         | SNHG3  | Median value | I–IV      | Reported in text        | No               | OS      | NO                     |
| Dong [24] | China  | 84          | PlncRNA-1 | Median value | I–IV    | Both                   | No               | OS      | NO                     |
| Shi [25]  | China  | 100         | Sox2ot  | Median ratio | I–IV      | Reported in text        | 60               | OS      | NO                     |
| Li [26]   | China  | 102         | ZEB1-AS1 | Median value | I–III    | Survival curve          | No               | OS      | NO                     |
| Shen [27] | China  | 84          | ACVR2B-AS1 | Median value | I–IV    | Both                   | No               | OS      | NR                     |
| Zhang [28] | China  | 109         | SNHG7  | Median value | —         | Reported in text        | 60               | OS      | NR                     |
| Zhang [29] | China  | 127         | SNHG4  | Median value | —         | Reported in text        | 60               | OS      | NR                     |
| Jiao [30] | China  | 320         | ENST0000042927.1 | Median value | I–IV    | Survival curve          | No               | OS      | NR                     |
| Xiao [31] | China  | 100         | HOTAIR | Median value | I–IV      | Reported in text        | 18.6             | OS      | NR                     |
| Zhao [32] | China  | 150         | GIHCG  | Median value | I–IV      | Reported in text        | 60               | OS      | NR                     |
| Zhang [33] | China  | 127         | LINC01296 | Median value | I–IV    | Survival curve          | No               | OS      | NR                     |
| Zhang [34] | China  | 337         | ENS347792.1 | Median value | I–IV    | Both                   | No               | OS      | NR                     |
| Zhang [35] | China  | 197         | HOXC13-AS | Median value | I–IV    | Survival curve          | No               | OS      | NR                     |
| Yu [36]   | China  | 123         | SUMO1P3 | Median value | I–IV      | Reported in text        | 60               | OS      | NR                     |
| Huang [37] | China  | 136         | ROR1-AS1 | Median value | I–IV    | Both                   | No               | OS      | NR                     |
| Tang [38] | China  | 55          | LncDQ  | Median value | I–IV      | Reported in text        | 60               | OS      | NR                     |
| Zhang [39] | China  | 127         | RHPN1-AS1 | Median value | I–IV    | Both                   | No               | OS      | NR                     |
| Bai [40]  | China  | 353         | PTTG3P | —            | I–IV      | Reported in text        | 72               | OS      | NR                     |
| Nie [41]  | China  | 371         | ACVR2B-AS1 | Median value | I–IV    | Both                   | No               | OS      | NR                     |
| Fu [42]   | China  | 122         | CCAT2  | Median value | I–IV      | Reported in text        | 60               | OS      | NR                     |
| Zhao [43] | China  | 161         | ENST0000042927.1 | Median value | I–IV    | Survival curve          | No               | OS      | NR                     |
| Pan [44]  | China  | 59          | circ0000267 | Median value | I–IV    | Survival curve          | No               | OS      | NR                     |
| Zhong [45] | China  | 108         | MIR210HG | Median value | I–IV    | Both                   | No               | OS      | NR                     |
| Wang [46] | China  | 326         | LINC0051 | Median value | I–IV    | Survival curve          | 72               | OS      | NR                     |
| Guo [47]  | China  | 61          | SNGH16  | Median value | I–IV      | Reported in text        | 60               | OS      | NR                     |
| Wang [48] | China  | 101         | ROR1-AS1 | Median value | I–IV    | Both                   | No               | OS      | NR                     |
| Wang [49] | China  | 159         | LINC01296 | Median value | I–IV    | Survival curve          | No               | OS      | NR                     |
| Xu [50]   | China  | 117         | AK021443 | Median value | I–IV    | Both                   | No               | OS      | NR                     |
| Zhao [51] | China  | 100         | GHET1  | Median ratio | —         | Reported in text        | 60               | OS      | NR                     |
| Zhang [52] | China  | 127         | RHPN1-AS1 | Median value | I–IV    | Both                   | No               | OS      | NR                     |
| Zeng [53] | China  | 130         | NC01296.1 | Median value | I–IV    | Both                   | No               | OS      | NR                     |
| Bai [54]  | China  | 127         | LINC01296 | Median value | I–IV    | Survival curve          | No               | OS      | NR                     |
| Nie [55]  | China  | 371         | ACVR2B-AS1 | Median value | I–IV    | Both                   | No               | OS      | NR                     |
| Fu [56]   | China  | 122         | CCAT2  | Median value | I–IV      | Reported in text        | 60               | OS      | NR                     |
| Zhao [57] | China  | 161         | ENST0000042927.1 | Median value | I–IV    | Survival curve          | No               | OS      | NR                     |
| Pan [58]  | China  | 59          | circ0000267 | Median value | I–IV    | Survival curve          | No               | OS      | NR                     |
| Zhong [59] | China  | 108         | MIR210HG | Median value | I–IV    | Both                   | No               | OS      | NR                     |

Note: Cutoff value: the critical value to distinguish between high and low lncRNA expression; OS: overall survival; DFS: disease-free survival; RFS: relapse-free survival; both: reported in text and survival curve; SDD: surgery to the date of death.
statistically significant (HR = 2.01, 95 CI% (1.57, 2.57), P < 0.01) Figure 4.

4. Discussion

Liver cancer has a very powerful, invasive, and aggressive ability, and it is prone to distant metastasis and recurrence, which leads to extremely mortality rate. In China, most patients with liver cancer are in an advanced stage when they are diagnosed, and the treatment methods and the effects are fantastically limited for them. Hence, the initial diagnosis and treatment of hepatic carcinoma remains a global difficulty and generates a large amount of discussion. Although there is an ongoing emergence of new drugs and treatments for liver cancer, there remain many difficulties in the early diagnosis and postoperative prognosis. Thus, the development of novel effective molecular therapeutic targets is the need of time to enhance the rate of diagnosis rate of liver cancer and the accuracy of prognosis judgment [56]. In recent years, according to detecting the tissues and plasma of cancer patients by real-time reverse transcription-polymerase chain reaction (RT-PCR), a high quantity of aberrantly expressed lncRNAs is found to participate in tumor metabolism to promote tumor development in different ways [57]. It has been found that only 1.5% of nucleic acid sequences were coding that is they make proteins while the rest 98.5% of the sequences are noncoding RNAs in three billion base pairs of the human genome, the latter regulated gene expression and maintained intracellular homeostasis through chromosome alteration, regulation of transcription,
Table 3: Results of meta-analysis on the correlation between LncRNA expression level and clinical features of liver cancer.

| Clinical Characteristics | Number of studies included (papers) | Tests for heterogeneity | Effect of the model | Results of meta-analysis |
|--------------------------|-------------------------------------|-------------------------|---------------------|--------------------------|
|                          |                                     | I² (%) | P value |                         | OR (95%CI) | P value |
| Age                      | 39 [5, 10, 16–52]                   | 66.5%  | <0.001 | Random                  | 1.07 (0.96, 1.19) | 0.253 |
| Gender                   | 42 [5, 10, 16–55]                   | 0.0%   | 0.66   | Fixed                   | 1.03 (0.92,1.15) | 0.648 |
| Tumor size               | 33 [10, 16, 29, 31, 34, 36, 39, 41–52] | 71.8%  | <0.001 | Random                  | 2.28 (2.00,2.60) | <0.001 |
| HBV infection            | 25 [10, 16, 19, 20, 24, 25, 27, 29, 31, 34, 36, 41, 43, 44, 46, 52, 55] | 0.0%   | 0.712  | Fixed                   | 1.12 (0.95,1.31) | 0.182 |
| Liver cirrhosis          | 18 [16, 20, 22, 25, 34, 38, 42, 44, 47, 49, 51, 55] | 0.0%   | 0.799  | Fixed                   | 1.39 (1.16,1.66) | <0.001 |
| Metastasis               | 28 [12, 23, 27, 28, 30, 32, 33, 35, 37, 39, 41, 42, 45, 48, 53, 54] | 71.8%  | <0.001 | Random                  | 2.28 (2.00,2.60) | <0.001 |
| HBV infection            | 28 [5, 8, 10, 15, 20, 22, 25, 28, 30, 32, 33, 35, 37, 39, 41, 42, 45, 48, 53, 54] | 0.0%   | 0.799  | Fixed                   | 1.39 (1.16,1.66) | <0.001 |
| AFP (400)                | 18 [10, 16, 22, 24, 26, 35, 41, 45, 47, 51, 52, 55] | 41.5%  | 0.034  | Fixed                   | 1.46 (1.22,1.75) | <0.001 |
| AFP (20)                 | 9 [27, 29, 40, 42, 43, 46, 48, 50] | 76.9%  | <0.001 | Random                  | 1.79 (1.40,2.29) | <0.001 |
| TNM stage                | 33 [5, 10, 15, 20, 22, 24, 29, 31, 34, 36, 43, 46, 58, 50, 51, 54] | 78.9%  | <0.001 | Random                  | 0.46 (0.41,0.51) | <0.001 |
| Tumor number             | 25 [10, 16, 24, 26, 30, 39, 34, 35, 37, 41, 42, 43, 46, 48, 50, 51, 55] | 53.4%  | 0.001  | Random                  | 0.72 (0.62,0.84) | <0.001 |
| V-invasion               | 22 [16, 19, 24, 26, 30, 39, 31, 34, 35, 37, 41, 42, 44, 45, 47, 49, 51, 55] | 84.7%  | <0.001 | Random                  | 2.02 (1.74,2.35) | <0.001 |

AFP (400): the cutoff of AFP is 400 μg/L; AFP (20): the cutoff of AFP is 20 μg/L; H-grade: histological grade; V-invasion: vascular invasion.

Figure 2: Forest plots for the relationship between the overexpressed LncRNA and OS. The center of each square represents the HR, the area of the square is the number of sample and the weight used in the meta-analysis, and the horizontal line indicates the 95%CI. CI indicates confidence interval; HR: hazard ratio.
LncRNA dysregulation can cause chromosomal loss and translocation, leading to the occurrence of cancer [58, 59]. LncRNA may be a potential biological target or as a molecular drug for prognosis and early diagnostic screening of cancer. At present, the relationship between lncRNA and tumor is attracting worldwide attention. Wang et al. [60] identified PVT1 to be highly expressed in hepatocellular carcinoma and related cell lines, and the affected individuals with increased PVT1 expression have a poor prognosis. PVT1 can increase the stability of nuclear protein NOP2, which helps cell proliferation, tumorigenesis, and gaining the same characteristics as exhibited by stem cells. Li et al. [61] found significantly increased HOTAIR expression level in liver cancerous tissues than paracarcinoma tissue. Besides, HOTAIR could downregulate the expression and phosphorylation of SETD2 to inhibit repair of DNA damage, causing microsatellite variability and aberrant cell cycle-related gene expression, which could further promote the occurrence of liver cancer. Yang [62] reported a crucially high expression level of noncoding RNA HEIH in affected individuals as compared to healthy ones. With the increase of the TNM stage, the expression of plasma HEIH increased gradually. LAN [63] found SNHG12 to be increasingly expressed in liver cancer-specific individuals and are connected with cancer size, TNM stage, and vascular invasion. Affected individuals with increased expression of SNHG12 had a worse prognosis and a higher recurrence rate than patients with low expression. SNHG12 can adsorb miR-199a/b-5p to increase the expression of MLK3 and its downstream effector molecule in the NF-κB pathway. Wang [64] reported that CARLo-5 is highly expressed in HCCLM3 and MHCC97-L cell lines and promotes the proliferation and metastasis of HCC, causing threats to the general and disease-free survival of affected individuals. These outcomes suggest that different types of lncRNA play different characters, but they all have significant roles in the growth and prognosis of liver cancer. Consequently, if one or more specific lncRNAs related to liver cancer are screened, chip technology, real-time quantitative RT-PCR, in situ hybridization technique, and other technologies can help in measuring the expression level of patients’ blood, urine, and other body fluids during clinical diagnosis and treatment, thereby improving the early diagnosis and prognosis of liver cancer.

The present work is the first one to analytically evaluate the relationship between the expression level of lncRNA and the clinical features and prognostic rate of affected individuals.
individually. The results show that vascular invasion, histological grade, number of tumors, size of the tumor, metastasis, and TNM stage of liver cancer patients are associated with the expression level of lncRNA. Furthermore, the patients with high expression of lncRNA have shorter OS, RFS, and DFS than those with low expression. The above results have statistically significant values, and the heterogeneity is very weak. So, the high expression of lncRNA may be a reason for decreased prognosis of hepatic carcinoma. But so far, the research on lncRNA is still in the preliminary stage. Currently, only a few lncRNAs are found, but there are still a high number of purposes and regulatory mechanisms of lncRNAs which are not clear. Moreover, these lncRNAs related to liver cancer have been confirmed by previous studies, but its clinical application in tumor diagnosis and treatment remain to be further explored. LncRNA has a good prospect of diagnosis and treatment, and it can become a new star of tumor marker in the future, providing new hope for the targeted therapeutic of hepatic carcinoma and the development of anticancer drugs.

Limitations of present work: (1) the comprised studies were retrospective studies, and the study design may have the risk of recall, measurement, and reporting bias; (2) the comprised research studies were all from China, due to differences in etiology, pathology, and prognosis in different regions. Therefore, this conclusion cannot be extended to other regions; (3) HRs of some included studies are not directly given relevant outcome indicators and only manually retrieved from the survival curve and then calculated, which may influence the validity of the results.

In conclusion, the highest expression of lncRNA in liver cancer patients is a poor prognosis factor for liver cancer. Owing to the limitations of the quantity and quality of researchers involved, the above deductions are subject to verification by further studies.

Abbreviations

RNA: Ribonucleic acid
lncRNA: Long noncoding RNA
TNM: Tumor, node, metastasis
OR: Odds ratio
95%CI: 95% confidence interval
ORF: Open reading frame
RT-PCR: Reverse transcription-polymerase chain reaction
OS: Overall survival
DFS: Disease-free survival
RFS: Relapse-free survival
HR: Hazard ratio
NOS: Newcastle–Ottawa Scale
PVT1: Plasmacytoma variant translocation 1
NOP2: Nucleolar protein 2
HOTAIR: HOX transcript antisense RNA
SETD2: SET domain containing 2.

Data Availability

The data could be obtained from contacting corresponding author.

Conflicts of Interest

The authors declare no conflicts of interest.

Authors’ Contributions

Leiqing Wang and Junzhi Sheng contributed equally to this work. Leiqing Wang and Jinjin Liu are in charge of the design and design of the study. Haojie Zhang, Baoyuan Xie, and Linbiao Xiang were responsible for the acquisition of data. Junzhi Sheng, Dong Liu, and Xinyuan Zhang interpreted the analysis. Leiqing Wang and Junzhi Sheng wrote the first draft of the manuscript and interpreted the data and wrote the final version.

Acknowledgments

This work was supported by the Gansu Natural Science Foundation Youth Project (20R10RA712) and the hospital fund of the First Hospital of Lanzhou University (ldyyyy2020-58).

References

[1] Y. J. Dong and L. R. Roberts, “Hepatocellular carcinoma: a global view,” Nat Rev Gastroenterol Hepatol, vol. 7, no. 8, pp. 448–458, 2010.
[2] P. C. Valery, M. Laversanne, P. J. Clark, J. L. Petrick, K. A. McGlynn, and F. Bray, “Projections of primary liver cancer to 2030 in 30 countries worldwide,” Hepatology (Baltimore, Md.), vol. 67, no. 2, pp. 600–611, 2018.
[3] L. A. Torre, F. Bray, R. L. Siegel, J. Ferlay, J. Lortet-Tieulent, and A. Jemal, “Global cancer statistics,” Ca A Cancer Journal for Clinicians, vol. 65, no. 2, pp. 87–108, 2012.
[4] F. Alessandro and B. Irene, “Long non-coding RNAs: new players in cell differentiation and development,” Nature Reviews Genetics, vol. 15, no. 1, pp. 7–21, 2014.
[5] H. Zhang, C. Zhuo, D. Zhou et al., “Small nucleolar RNA host gene 1 (SNHG1) and chromosome 2 open reading frame 48 (C2orf48) as potential prognostic signatures for liver cancer by constructing regulatory networks,” Medical Science Monitor, vol. 26, 2020 Feb 9 PMID: 32036380; PMCID: PMC7029818, Article ID e920482.
[6] J. R. Prensner and A. M. Chinnaiyan, “The emergence of lncRNAs in cancer biology,” Cancer Discovery, vol. 1, no. 5, pp. 391–407, 2011.
[7] J. T. Y. Kung, D. Colognori, and J. T. Lee, “Long noncoding RNAs: past, present, and future,” Genetics, vol. 193, no. 3, pp. 651–669, 2013.
[8] J. E. Wilusz, H. Sunwoo, and D. L. Spector, “Long noncoding RNAs: functional surprises from the RNA world,” Genes & Development, vol. 23, no. 13, pp. 1494–1504, 2009.
[9] R. A. Gupta, N. Shah, K. C. Wang et al., “Long non-coding RNA HOTAIR reprograms chromatin state to promote cancer metastasis,” Nature, vol. 464, no. 7291, pp. 1071–1076, 2010.
[10] M. Huang, J. Hou, Y. Wang et al., “Long noncoding RNA LINC00673 is activated by SP1 and exerts oncogenic properties by interacting with LSD1 and EZH2 in gastric cancer,” Molecular Therapy, vol. 25, no. 4, pp. 1014–1026, 2017.
[11] G. Yang, X. Lu, and L. Yuan, “LncRNA: a link between RNA and cancer,” Biochimica et Biophysica Acta (BBA) - Gene
Journal of Healthcare Engineering

Regulatory Mechanisms, vol. 1839, no. 11, pp. 1097–1109, 2014.

[12] L. Shi, F. Peng, Y. Tao, X. Fan, and N. Li, “Roles of long noncoding RNAs in hepatocellular carcinoma,” Virus Research, vol. 223, no. 1, pp. 131–139, 2016.

[13] Z. Zhou, T. Zhang, B. Li, F. Yan, H. Liu, and W. Jiang, “Extraction and transformation of meta-analysis suitable data in survival curve,” Chinese Journal of Evidence-Based Cardiovascular Medicine, vol. 6, no. 3, pp. 243–247, 2014.

[14] J. P. A. Ioannidis and T. A. Trikalinos, “Proper application of asymmetry tests for publication bias in meta-analyses: a large survey,” Canadian Medical Association Journal, vol. 176, no. 8, pp. 1091–1096, 2007.

[15] S. Guo, W. Chen, Y. Luo et al., “Clinical implication of long non-coding RNA NEAT1 expression in hepatocellular carcinoma,” Experimental Pathology, vol. 8, no. 5, pp. 5395–402, 2015.

[16] J. Li, J. Xie, Z. Liao et al., “High expression of long non-coding RNA GHET1 is associated with unfavorable prognosis in hepatocellular carcinoma,” International Journal of Clinical and Experimental Medicine, vol. 10, no. 2, pp. 2374–2385, 2017.

[17] F. Wang, H. Yang, Z. Deng, Y. Su, Q. Fang, and Z. Yin, “HOX antisense lincRNA HOXA-AS2 promotes tumorigenesis of hepatocellular carcinoma,” Cellular Physiology and Biochemistry, vol. 40, no. 1-2, pp. 287–296, 2016.

[18] T. Zhou and Y. Gao, “Increased expression of LncRNA BANCR and its prognostic significance in human hepatocellular carcinoma,” World Journal of Surgical Oncology, vol. 14, no. 1, pp. 1–8, 2015.

[19] Z. H. Ding, L. Jiang, R. H. Huang et al., Increased Expression of Long Non-coding RNA TUG1 Associates with Poor Prognosis of Hepatocellular Carcinoma, International Journal of Clinical and Experimental Pathology, 2017.

[20] C. Ding, Z. Yang, Z. Lv et al., “Long non-coding RNA PVT1 is associated with tumor progression and predicts recurrence in hepatocellular carcinoma patients,” Oncology Letters, vol. 9, no. 2, pp. 955–963, 2015.

[21] Z. Yang, L. Zhou, L.-M. Wu et al., “Overexpression of long non-coding RNA HOTAIR predicts tumor recurrence in hepatocellular carcinoma patients following liver transplantation,” Annals of Surgical Oncology, vol. 18, no. 5, pp. 1243–1250, 2011.

[22] T. H. Yan, H. Yang, J. H. Jiang et al., “Prognostic significance of long non-coding RNA PCAT-1 expression in human hepatocellular carcinoma,” International Journal of Clinical and Experimental Pathology, vol. 8, no. 4, pp. 4126–4131, 2015.

[23] T. Zhang, C. Cao, D. Wu, and L. Liu, “SNHG3 correlates with malignant status and poor prognosis in hepatocellular carcinoma,” Tumor Biology, vol. 37, no. 2, pp. 2379–2385, 2016.

[24] L. Dong, J. Ni, W. Hu, C. Yu, and H. Li, “Upregulation of long non-coding RNA PhlncRNA-1 promotes metastasis and induces epithelial-mesenchymal transition in hepatocellular carcinoma,” Cellular Physiology and Biochemistry, vol. 38, no. 2, pp. 836–846, 2016, Epub 2016 Feb 24. PMID: 26906068.

[25] X. M. Shi and F. Teng, “Up-regulation of long non-coding RNA Sox2ot promotes hepatocellular carcinoma cell metastasis and correlates with poor prognosis,” International Journal of Clinical and Experimental Pathology, vol. 8, no. 4, pp. 4008–4014, 2015.

[26] T. Li, J. Xie, C. Shen et al., “Upregulation of long noncoding RNA ZEB1-AS1 promotes tumor metastasis and predicts poor prognosis in hepatocellular carcinoma,” Oncogene, vol. 35, no. 12, pp. 1575–1584, 2016.

[27] A. Shen, J. Ma, X. Hu, and X. Cui, “High expression of IncRNA-SNHG7 is associated with poor prognosis in hepatocellular carcinoma,” Oncology Letters, vol. 19, no. 6, pp. 3959–3963, 2020 Jun, Epub 2020 Mar 27. PMID: 32382340.

[28] Z. Zhang, J. Z. Li, Z. W. Wei et al., “Correlation between expression levels of IncRNA UCA1 and miR-18a with prognosis of hepatocellular cancer,” European Review for Medical and Pharmacological Sciences, vol. 24, no. 7, pp. 3586–3591, 2020 Apr.

[29] X. Zhang, Z. Yan, L. Wang, S. Zhang, and M. Gao, “STAT1-induced upregulation of IncRNA RHPN1-AS1 predicts a poor prognosis of hepatocellular carcinoma and contributes to tumor progression via the miR-485/CDC5 axis,” Journal of Cellular Biochemistry, vol. 121, no. 12, pp. 4741–4755, 2020 Feb 17, Epub ahead of print. PMID: 32065447.

[30] Y. Jiao, Y. Li, B. Jia et al., “The prognostic value of IncRNA SNHG4 and its potential mechanism in liver cancer,” Biotechnology Reports, vol. 40, no. 1, Article ID BSR20190729, 2020 Jan 31.

[31] S. Xiao, S. Huang, and J. Yang, “Overexpression of GHIHG5 is associated with a poor prognosis and immune infiltration in hepatocellular carcinoma,” OncoTargets and Therapy, vol. 13, pp. 11607–11619, 2020 Nov 12, PMID: 33209037; PMCID: PMC7670177.

[32] Z. Zhang, S. Wang, F. Yang, Z. Meng, and Y. Liu, “LncRNA ROR1-AS1 high expression and its prognostic significance in liver cancer,” Oncol Rep, vol. 43, no. 1, pp. 55–74, 2020 Jan.

[33] Y. Nie, Y. Jiao, Y. Li, and W. Li, “Investigation of the clinical significance and prognostic value of the IncRNA ACVR2B-AS1 in liver cancer,” BioMed Research International, vol. 2019, Article ID 4602371, 13 pages, 2019 Oct.

[34] C. Fu, X. Xu, W. Lu, L. Nie, T. Yin, and D. Wu, “Increased expression of long non-coding RNA CCAT2 predicts poorer prognosis in patients with hepatocellular carcinoma,” Medicine, vol. 98, no. 42, PMID: 31626095, Article ID e17412, 2019 Oct.

[35] Y. Zhao, C.-Q. Kong, J.-Z. Ye et al., “Upregulation of long non-coding RNA ENST000004292271 is correlated with poor prognosis in human hepatocellular carcinoma,” Medical Science Monitor, vol. 25, pp. 6539–6546, 2019 Aug 31, PMID: 31427071; PMCID: PMC6738009.

[36] H. Pan, L. Tang, H. Jiang et al., “Enhanced expression of circ_0000267 in hepatocellular carcinoma indicates poor prognosis and facilitates cell progression by sponging miR-646,” Journal of Cellular Biochemistry, vol. 120, no. 7, pp. 11350–11357, 2019 Feb 5, Epub ahead of print. PMID: 30719761.

[37] R. P. Wang, J. Jiang, T. Jiang, Y. Wang, and L. X. Chen, “Increased long noncoding RNA LINCO00511 is correlated with poor prognosis and contributes to cell proliferation and metastasis by modulating miR-424 in hepatocellular carcinoma,” European Review for Medical and Pharmacological Sciences, vol. 23, no. 8, pp. 3291–3301, 2019 Apr.

[38] Z. Guo, J. Zhang, L. Fan et al., “Long noncoding RNA (IncRNA) small nucleolar RNA host gene 16 (SNHG16) predicts poor prognosis and sorafenib resistance in hepatocellular carcinoma,” Medical Science Monitor, vol. 25, pp. 2079–2086, 2019 Mar 20, PMID: 30893293; PMCID: PMC6437716.

[39] Y. Wang, W. Li, X. Chen, Y. Li, P. Wen, and F. Xu, “MIR210HG predicts poor prognosis and functions as an oncogenic lncRNA in hepatocellular carcinoma,” Biomedicine & Pharmacotherapy, vol. 111, pp. 1297–1301, 2019 Mar, Epub 2019 Jan 15. PMID: 30841443.
[40] Z. C. Wang, S. Yang, M. Q. Chen, S. S. Wu, H. H. Lv, and W. X. Jin, "LINC01296 promotes the proliferation and invasion by regulating microRNA-760 expression and predicts poor prognosis of hepatocellular carcinoma," European Review for Medical and Pharmacological Sciences, vol. 23, no. 22, pp. 9848–9856, 2019 Nov.

[41] J. F. Zhou, Y. T. Shi, H. G. Wang, X. Z. Yang, and S. N. Wu, "Overexpression of long noncoding RNA HOXC13-AS and its prognostic significance in hepatocellular carcinoma," European Review for Medical and Pharmacological Sciences, vol. 23, no. 17, pp. 7369–7374, 2019 Sep.

[42] H. Yu, Y. Bai, C. Xu, X. He, Q. Liu, and D. Ma, "The tissue expression levels of SUMO1P3 may be a reliable prognostic biomarker to predict the clinical outcomes in patients with HCC," Medicine (Baltimore), vol. 99, no. 46, PMID: 33181633, Article ID e21291, 2020 Nov 13.

[43] J. L. Huang, S. W. Cao, Q. S. Ou et al., "Long non-coding RNA PTTG3P promotes cell growth and metastasis via up-regulating PTTG1 and activating PI3K/AKT signaling in hepatocellular carcinoma," Mol Cancer, vol. 17, no. 1, p. 93, 2018 May 26 PMID: 29803324; PMCID: PMC5970477.

[44] R. Tang, J. C. Wu, L. M. Zheng et al., "Long noncoding RNA RUSC1-AS-N indicates poor prognosis and increases cell viability in hepatocellular carcinoma," Eur Rev Med Pharmacol Sci, vol. 22, no. 2, pp. 388–396, 2018 Jan.

[45] H. Qi, Y. Lu, J. Lv et al., "The long noncoding RNA IncPAP1 contributes to progression of hepatocellular carcinoma through up-regulation of PARP1," Biosci Rep, vol. 38, no. 3, Article ID BSR20180703, 2018 Jun 21.

[46] X. L. Jin, J. R. Lian, and Y. H. Guan, "Overexpression of long non-coding RNA MRNCR contributes to progressive clinicopathological features and poor prognosis of human hepatocellular carcinoma," Eur Rev Med Pharmacol Sci, vol. 22, no. 23, pp. 8197–8202, 2018 Dec.

[47] C. Xu, Q. Huang, C. Zhang et al., "Long non-coding RNA TRPM2-AS as a potential biomarker for hepatocellular carcinoma," Irish Journal of Medical Science, vol. 187, no. 3, pp. 621–628, 2018 Aug, Epub 2017 Oct 28. PMID: 29801064.

[48] Y. C. Li, D. Wang, and G. Y. Zhu, "Increased expression of long noncoding RNA AK021443 predicts worse clinical outcome in hepatocellular carcinoma," European Review for Medical and Pharmacological Sciences, vol. 22, no. 15, pp. 4855–4860, 2018 Aug.

[49] L. Jin, Y. He, S. Tang, and S. Huang, "LncRNA GHET1 predicts poor prognosis in hepatocellular carcinoma and promotes cell proliferation by silencing KLF2," Journal of Cellular Physiology, vol. 233, no. 6, pp. 4726–4734, 2018 Jun, Epub 2017 Dec 26. PMID: 29139562.

[50] Z. F. Wang, R. Hu, J. M. Pang, G. Z. Zhang, W. Yan, and Z. N. Li, "Serum long noncoding RNA LRBI as a potential biomarker for predicting the diagnosis and prognosis of human hepatocellular carcinoma," Oncol Lett, vol. 16, no. 2, pp. 1593–1601, 2018 Aug, PMID: 30008842.

[51] B. Zeng, Z. Lin, H. Ye et al., "Upregulation of LncDQ is associated with poor prognosis and promotes tumor progression via epigenetic regulation of the EMT pathway in HCC," Cell Physiol Biochem, vol. 46, no. 3, pp. 1122–1133, 2018, Epub 2018 Apr 13. PMID: 29699339.

[52] J. Liang, D. Wang, G. Qiu et al., "Long noncoding RNA FOXP4-AS1 predicts unfavourable prognosis and regulates proliferation and invasion in hepatocellular carcinoma," BioMed Research International, vol. 2021, Article ID 8850656, 12 pages, 2021 Feb 1.